These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8402458)

  • 1. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer.
    Høgdall CK; Christensen L; Clemmensen I
    Cancer; 1993 Oct; 72(8):2415-22. PubMed ID: 8402458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human tetranectin: methodological and clinical studies.
    Høgdall CK
    APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients.
    Høgdall CK; Høgdall EV; Hørding U; Clemmensen I; Nørgaard-Pedersen B; Toftager-Larsen K
    Scand J Clin Lab Invest; 1993 Nov; 53(7):741-6. PubMed ID: 8272761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
    Høgdall CK; Nørgaard-Pedersen B; Mogensen O
    Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in tetranectin immunoreactivity between benign and malignant breast tissue.
    Christensen L; Clemmensen I
    Histochemistry; 1991; 95(5):427-33. PubMed ID: 1651300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the 'Malova' ovarian cancer study.
    Heeran MC; Rask L; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Jarle Christensen IB; Høgdall EV
    APMIS; 2015 May; 123(5):401-9. PubMed ID: 25846370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
    Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
    Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
    Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
    Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.
    Deng X; Høgdall EV; Høgdall CK; Nørgaard-Pedersen B; Jørgensen M; Nielsen H; Engelholm SA
    Gynecol Oncol; 2000 Dec; 79(3):416-9. PubMed ID: 11104612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tetranectin, a plasma and tissue protein--a prognostic marker of breast and ovarian cancer].
    Høgdall CK; Christensen L; Clemmensen I
    Ugeskr Laeger; 1994 Oct; 156(42):6190-5. PubMed ID: 7998355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA.
    Høgdall CK; Christensen IJ; Stephens RW; Sørensen S; Nørgaard-Pedersen B; Nielsen HJ
    APMIS; 2002 Sep; 110(9):630-8. PubMed ID: 12529016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tetranectin and CA125 in endometrial adenocarcinoma.
    Lundstrøm MS; Høgdall CK; Nielsen AL; Nyholm HC
    Anticancer Res; 2000; 20(5C):3903-6. PubMed ID: 11268474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian carcinoma serum markers and ovarian steroid activity--is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CA-125 to ovarian activity and the gonadotropin levels.
    Blaakaer J; Høgdall CK; Micic S; Toftager-Larsen K; Hørding U; Bennett P; Bock J
    Eur J Obstet Gynecol Reprod Biol; 1995 Mar; 59(1):53-6. PubMed ID: 7781862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tetranectin and CA-125 used to monitor the course of treatment in ovarian cancer patients.
    Høgdall CK; Hørding U; Nørgaard-Pedersen B; Toftager-Larsen K; Clemmensen I
    Eur J Obstet Gynecol Reprod Biol; 1994 Dec; 57(3):175-8. PubMed ID: 7713292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tetranectin in patients with acute pelvic inflammatory disease (PID). Correlation to clinical and laboratory findings.
    Høgdall CK; Christiansen M; Brihmer C
    Acta Obstet Gynecol Scand; 1995 Mar; 74(3):203-7. PubMed ID: 7534970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma tetranectin and ovarian neoplasms.
    Høgdall CK; Høgdall EV; Hørding U; Daugaard S; Clemmensen I; Nørgaard-Pedersen B; Toftager-Larsen K
    Gynecol Oncol; 1991 Nov; 43(2):103-7. PubMed ID: 1743549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma tetranectin and colorectal cancer.
    Høgdall CK; Christiansen M; Nørgaard-Pedersen B; Bentzen SM; Kronborg O; Clemmensen I
    Eur J Cancer; 1995 Jun; 31A(6):888-94. PubMed ID: 7646916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of serum tetranectin: technical and clinical evaluation of three sandwich immunoassays.
    Thougaard AV; Høgdall CK; Kjaer SK; Blaakaer J; Jaliashvili I; Christiansen M
    Clin Chim Acta; 1998 Aug; 276(1):19-34. PubMed ID: 9760017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients.
    Begum FD; Høgdall E; Christensen IJ; Christensen L; Kjaer SK; Blaakaer J; Petri AL; Høgdall C
    Gynecol Oncol; 2010 Jun; 117(3):446-50. PubMed ID: 20304468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.